Latest Conference Articles

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

July 7th 2025

ADA

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions

ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions

June 20th 2025

ADA

The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.

2025 ACOG Annual Clinical & Scientific Meeting: What You May Have Missed

2025 ACOG Annual Clinical & Scientific Meeting: What You May Have Missed

June 10th 2025

ACOG

From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.

Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis

Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis

June 6th 2025

Revolutionizing Atopic Dermatitis (RAD)

RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.

INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis

INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis

June 6th 2025

Revolutionizing Atopic Dermatitis (RAD)

RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.

Women’s Health Takeaways for Primary Care: Expert Insights From ACOG 2025

Women’s Health Takeaways for Primary Care: Expert Insights From ACOG 2025

June 6th 2025

ACOG

Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.

Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD

Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD

June 3rd 2025

ACOG

ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.

Provider Gaps in Postpartum Depression Screening and Management Highlighted in New Study

Provider Gaps in Postpartum Depression Screening and Management Highlighted in New Study

May 28th 2025

ACOG

ACOG 2025: Laxmi Gannu, MS, discusses key findings from a provider survey on postpartum depression screening practices, training gaps, and referral patterns.

Tailoring Weight Management Conversations Across a Woman’s Lifespan

Tailoring Weight Management Conversations Across a Woman’s Lifespan

May 27th 2025

ACOG

Johanna Finkle, MD, outlines how clinicians can adapt weight management counseling during key stages of a woman’s life, from preconception through menopause.

The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care

The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care

May 22nd 2025

ACOG

At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.